- Joined
- Jan 13, 2015
- Messages
- 50
- Reaction score
- 51
A few months ago, I learned about the updated ACR recommendations regarding contrast-induced AKI (see below). However, when I attempt to convince my attendings/coresidents to be more liberal with their use of contrast I'm usually met with an "oh, precious" look and polite rejection. Has anyone had better luck? If so, any suggestions?
From the manual on contrast media:
"Unfortunately, very few published studies have a suitable control group to permit the separation of contrast-induced nephropathy from post-contrast acute kidney injury. At the current time, it is the position of the ACR Committee on Drugs and Contrast Media that CIN is a real, albeit rare, entity. Published studies on CIN have been heavily contaminated by bias and conflation."
"There is no agreed-upon threshold of serum creatinine elevation or eGFR declination beyond which the risk of CIN is considered so great that intravascular iodinated contrast medium should never be administered. At the current time, there is very little evidence that IV iodinated contrast material is an independent risk factor for AKI in patients with eGFR >30. Therefore, if a threshold for CIN risk is used at all, 30 seems to be the one with the greatest level of evidence."
...and a related article:
"AKI temporally related to contrast material administration, a common occurrence in hospitalized patients, is often blamed on contrast material and not on one of potentially many other coexistent factors."
"Almost all prospective and retrospective studies investigating the nephrotoxic potential of iodinated contrast media have failed to disentangle contrast-induced AKI from post-contrast AKI, leading to confusing and sometimes uninterpretable results."
"...a series of recent large-scale (>10,000 patients each) propensity-adjusted studies have assessed the risk of costrast-induced AK. Each of these studies shows with excellent power that the per-patient risk of contrast-induced AKI after IV contrast administration is either rare or non-existent for patients with a stable eGFR of >45."
"However, the studies reached different conclusions for patients with an eGFR <45. Specifically, those with an eGFR of 30-44 were determined to be at either borderline increased risk or no risk, and those with an eGFR <30 were determined to be at either substantially increased risk or no risk."
"Assuming the worst-case point estimates among these studies, the number needed to harm would compute to 39 contrast administrations for one case of contrast-induced AKI in patients with an eGFR of 30-44 and to 6 contrast administrations for one case of contrast-induced AKI in patients with an eGFR of <30."
From the manual on contrast media:
"Unfortunately, very few published studies have a suitable control group to permit the separation of contrast-induced nephropathy from post-contrast acute kidney injury. At the current time, it is the position of the ACR Committee on Drugs and Contrast Media that CIN is a real, albeit rare, entity. Published studies on CIN have been heavily contaminated by bias and conflation."
"There is no agreed-upon threshold of serum creatinine elevation or eGFR declination beyond which the risk of CIN is considered so great that intravascular iodinated contrast medium should never be administered. At the current time, there is very little evidence that IV iodinated contrast material is an independent risk factor for AKI in patients with eGFR >30. Therefore, if a threshold for CIN risk is used at all, 30 seems to be the one with the greatest level of evidence."
...and a related article:
"AKI temporally related to contrast material administration, a common occurrence in hospitalized patients, is often blamed on contrast material and not on one of potentially many other coexistent factors."
"Almost all prospective and retrospective studies investigating the nephrotoxic potential of iodinated contrast media have failed to disentangle contrast-induced AKI from post-contrast AKI, leading to confusing and sometimes uninterpretable results."
"...a series of recent large-scale (>10,000 patients each) propensity-adjusted studies have assessed the risk of costrast-induced AK. Each of these studies shows with excellent power that the per-patient risk of contrast-induced AKI after IV contrast administration is either rare or non-existent for patients with a stable eGFR of >45."
"However, the studies reached different conclusions for patients with an eGFR <45. Specifically, those with an eGFR of 30-44 were determined to be at either borderline increased risk or no risk, and those with an eGFR <30 were determined to be at either substantially increased risk or no risk."
"Assuming the worst-case point estimates among these studies, the number needed to harm would compute to 39 contrast administrations for one case of contrast-induced AKI in patients with an eGFR of 30-44 and to 6 contrast administrations for one case of contrast-induced AKI in patients with an eGFR of <30."